INTRODUCTION

Adult T-cell leukemia/lymphoma (ATLL) is a malignancy of peripheral T lymphocytes infected by human T-lymphotropic virus type I (HTLV-1).
1 On the basis of the recommendation of an international consensus meeting devoted to ATLL, intensive chemotherapy (for example, a VCAP (vincristine, cyclophosphamide, doxorubicin, prednisone)-AMP (doxorubicin, ranimustine, prednisone)-VCEP (vindesine, etoposide, carboplatin, prednisone) regimen 2 ) has been proposed as the first-line treatment for aggressive ATLL; however, the overall clinical outcome still remains dismal: [3] [4] [5] [6] the median PFS in patients treated with the VCAP-AMP-VECP regimen is no more than 7.0 months. 4 Furthermore, the completion rate of the regimen is rather low (32%) because of high toxicities and relapse/progression. 4 This situation has led hematologists to focus their attention on allogeneic hematopoietic SCT (allo-HSCT) as a realistic treatment option for patients with aggressive ATLL. 2 In addition, previous studies in Japan revealed that a substantial proportion of patients with ATLL who receive allo-HSCT achieve durable disease-free survival. [7] [8] [9] Although the overall prognosis of patients with aggressive ATLL is poor, a large proportion of patients initially respond, at least to some extent, to induction chemotherapies. This observation has led physicians to reasonably assume that allo-HSCT, applied at an early phase of disease regression induced by initial treatment, could improve overall clinical prognosis of these patients when a suitable related donor is available. Probably because the nationwide transplant database embraces ATLL patients who received allo-HSCT from both related and unrelated donors, previous studies in Japan that used this database never discussed the issue from this viewpoint, even when those reports assessed the impact of time from diagnosis to transplant. Furthermore, the late HSCT cohort (e.g., patients for whom time from diagnosis to transplantation is more than 6 months) contains more patients with ATLL who received HSCT from unrelated donors, requiring more time for donor acquisition. Accordingly, the elevated proportion of unrelated HSCT could obscure the impact of the timing of allo-HSCT in the context of transplant from related donors.
Hence, in order to attempt to clearly evaluate the impact of timing of allo-HSCT for patients with ATLL, we retrospectively analyzed data from patients with ATLL who first received an allo-HSCT from a related donor, using information from the database of Japan Society for Hematopoietic Cell Transplantation (JSHCT).
PATIENTS AND METHODS
Data collection
Management Program. 10 We exclusively analyzed patients for whom information on the interval between diagnosis of ATLL and allo-HSCT was available, and excluded patients for whom survival status data were not available. A total of 500 patients met the criteria. This study was planned by the ATLL working group of Japan Society for Hematopoietic Cell Transplantation, and was approved by the data management committees of Transplant Registry Unified Management Program and the institutional review board of the National Cancer Center, Tokyo, Japan.
End points and statistical analyses
The primary end point of this study was the probability of OS. Secondary end points were the cumulative incidences of non-relapse mortality (NRM) and relapse. Physicians who practiced transplantations at each center diagnosed and graded acute GVHD according to the standard criteria.
11
A descriptive statistical analysis was performed to assess the patients' characteristics. The medians and ranges are provided for continuous variables, and percentages are shown for categorical variables. The patient's characteristics were compared using the χ 2 -test or Fisher's exact test for categorical variables. The probability of OS was calculated by the Kaplan-Meier method. A Cox proportional hazards regression model was employed to analyze OS. The cumulative incidences of NRM and GVHD were evaluated using the model of Fine and Gray for univariate and multivariate analyses, respectively. 12 In the competing-risk models for GVHD, relapse and death before these events were defined as competing risks. In the competing-risk model for NRM, relapse was defined as a competing risk. Factors that were associated with a two-sided P-value of less than 0.10 in the univariate analysis were included in a multivariate analysis. We used a backward-stepwise selection algorithm and retained only statistically significant variables in the final model. A two-sided P-value of less than 0.05 was considered statistically significant. The variables that were evaluated in these analyses were as follows: sex mismatch (female to male vs others), patient's age at the time of HSCT (age ⩾ 50 years vs age o50), disease status (CR vs non-CR), stem cell source (BM vs PBSCs), ABO mismatch, performance status (PS, 0-1 vs 2-4), intensity of the conditioning regimen (myeloablative vs reduced intensity), GVHD prophylaxis (CYA-based vs tacrolimus-based), year of transplant (⩾ 2007 vs o 2007) and HLA disparity. All statistical analyses were performed using EZR (Saitama Medical Centre, Jichi Medical University; http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN. html), a graphical user interface for R (version 3.0.2; The R Foundation for Statistical Computing, Vienna, Austria). 13 More precisely, EZR is a modified version of R commander (version 2.0.3) that incorporates statistical functions frequently used in biostatistics.
RESULTS
Patient characteristics
Patient characteristics are summarized in Table 1 . The median age was 52 years. Patients were grouped according to the interval from diagnosis to allo-HSCT: early transplant group, o 100 days, n = 72; late transplant group, ⩾100 days, n = 428. Non-CR status before transplant was more frequent in the late transplant group, although the difference was not statistically significant (P = 0.11), and there was no significant difference in the other corresponding constituents (Table 1) .
Clinical outcome
The median follow-up period of survivors was 1686 days (range, 70-5071 days) after allo-HSCT. The probability of 4-year OS in the whole cohort was 32.5% (95% confidence interval (CI), 28.2-36.9%; Figure 1a ). The probability of OS was significantly higher in the early transplant group than in the late transplant group (4-year OS, 49.3% vs 31.2%; P = 0.01; Figure 1b ). Multivariate analysis revealed that late allo-HSCT was an unfavorable prognostic factor for OS (hazard ratio, 1.46; 95% CI, 1.01-2.11; P = 0.042; Table 2 ). Because we observed an imbalance (albeit a statistically insignificant one) between the two groups in disease status before transplantation, we conducted a subgroup analysis. In patients with CR, the probability of 4-year OS tended to be higher in the early transplant group than in the late transplant group (4-year OS, 60.7% vs 40.8%; P = 0.13; Figure 1c ), whereas in non-CR patients the probability of 4-year OS was significantly higher in the early Abbreviations: ATL = aggressive adult T-cell leukemia; HTLV I = human T-lymphotropic virus type I; MAC = myeloablative conditioning; RIC = reduced-intensity conditioning.
Early allo-HSCT in ATL S Fuji et al transplant group than in the late transplant group (4-year OS, 37.6% vs 24.5%; P = 0.04; Figure 1d ). Even when we divided the late transplant group into two subgroups (time from diagnosis to SCT, 100-179 and ⩾ 180 days), patients who received SCT o 100 days had a better OS compared with both groups (4-year OS, o100 days, 47.2%; 100-179 days, 29.4%; 4180 days, 30.3%), and it was statistically significant (100-179 days, hazards ratio 1.60, 95% CI 1.12-2.29, P o 0.05 vs o100 days; 4180 days, hazards ratio 1.61, 95% CI 1.13-2.29, P o0.05 vs o 100 days).
In a univariate analysis, the cumulative incidence of NRM was lower in the early transplant group than in the late transplant group, although the difference was not significant (4-year NRM, 18.6% vs 30.7%; P = 0.07; Figure 2a , Table 3 ). However, in a multivariate analysis, no variable (including interval from diagnosis to allo-HSCT) had a statistically significant effect on NRM. When we focused on NRM at 1 year, we found that the cumulative incidence was higher in the late transplant group than in the early transplant group (26.0% vs 9.8%, P o0.01). In addition, both the cumulative incidences of 1-year infection-related NRM and GVHD-related NRM tended to be higher in the late transplant group (4.8 and 10.1%) than in the early transplant group (1.4 and 0.0%). The cumulative incidence of relapse did not differ between the two groups ( Figure 2b , Table 4 ).
DISCUSSION
The results of this study demonstrate, for the first time, that early application of allo-HSCT from related donors has a positive influence on clinical outcome in patients with ATLL. Early allo-HSCT was determined as similar timing of allo-HSCT in a previous report of early allo-HSCT for high-risk AML, in which time from diagnosis to allo-HSCT was o 100 days in all included patients.
14 A retrospective study such as this one has several limitations; nonetheless, given the favorable outcome in the early transplant group, it might be reasonable to consider early application of allo-HSCT for cases of ATLL.
In this study, the improved outcome of ATLL patients who underwent the early transplant can be attributed, at least in part, to the lower incidence of NRM in the early period after transplant (early NRM). In addition, the incidences of both infection-related and GVHD-related death also increased in the late transplant group, although without statistical significance. Although the built-in limitations of registry data make it difficult to elucidate Abbreviations: ATL = aggressive adult T-cell leukemia; CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; HSCT = hematopoietic SCT; PS = performance status.
Early allo-HSCT in ATL S Fuji et al the mechanism underlying the lower incidence of early NMR in the early transplant group, we assume that repeated cycles of intensive chemotherapy aimed at controlling ATLL disease status are often associated with elevated risk of morbidities such as infectious diseases and organ failures. This phenomenon is likely to be related to the failure to control infectious disease and GVHD following allo-HSCT that we observed in the late transplant group. Considering the dismal clinical outcomes resulting from intensive chemotherapies alone, it seems reasonable to consider allo-HSCT for all eligible patients with ATLL. Intensive chemotherapy for patients with ATLL is often effective for several cycles; however, it is practically difficult to complete the planned six cycles because of high toxicities as previously reported. 4 Furthermore, even the responsive patients ultimately relapse. 4 In addition, similar to other peripheral T-cell lymphoma, relapsed ATLL is often refractory to salvage chemotherapies. 15 Taking these poor clinical outcomes into consideration, it is likely that early application of allo-HSCT for patients with ATLL will be able to improve the clinical outcome as in high-risk AML.
14 Such an early application of allo-transplant using cord blood transplantation (CBT) has been clinically attempted in patients with ATLL for whom a suitable related donor could not be acquired in a timely manner, yielding represented promising results relative to CBT, as revealed by the registry data. 8, [16] [17] [18] Here, we demonstrated a survival advantage in ATLL patients who underwent early application of allo-HSCT from related donors. Furthermore, the results of CBT suggest that early application of allo-HSCT is promising for patients with ATLL, even those who lack an HLAmatched related donor. Considering recent promising results obtained using post-transplant CY after allo-HSCT using stem cells from an HLA-haploidentical related donor, 19, 20 early application of haploidentical HSCT should be also explored in patients with ATLL. 21 Extending the concept that the proper time for allo-HSCT for patients with ATLL falls within the early phase of initial treatment, we are launching a clinical trial of early allo-HSCT for ATLL patients who lack HLA-matched sibling donors, using alternative stem cell sources that become available in a timely manner. In addition, optimization of transplant regimens for alternative donors, including unrelated, cord blood and haploidentical related donors, should be explored in parallel.
Finally, the limitations in this study should be addressed. Although this was the largest study to assess the impact of timing of related-donor HSCT on clinical outcome in patients with ATLL, it was a retrospective analysis. Therefore, we were unable to fully exclude uncontrolled confounding variables, even if we 
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Early allo-HSCT in ATL S Fuji et al conducted multivariate analyses for each clinical outcome. In addition, because of a nature of our SCT registry data, no data about chemotherapy regimens before SCT was available. The impact of type, cycle and responsiveness of previous chemotherapy regimens should be clarified in more detail in the future study.
In conclusion, we demonstrated a survival advantage in ATLL patients who underwent early application of allo-HSCT from related donors. This study had several limitations inherent to its retrospective nature. Nonetheless, in light of the favorable outcome in the early transplant group, it might be reasonable to consider early application of allo-HSCT for the treatment of patients with ATLL. Abbreviations: CI = confidence interval; HSCT = hematopoietic SCT; NRM = non-relapse mortality; NR = non-remission; PS = performance status.
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